Study study type PathologyT1T0Patientssample sizesROB Results

lung cancer : non small cell (NSCLC) lung cancer : non small cell (NSCLC)

versus no control (uncontrolled study)
entrectinib
ALKA-372-001, STARTRK-1, STARTRK-2 (lung cancer), 2020
  NCT02568267
DESClung cancer : non small cell (NSCLC)entrectinib ≥ 600 mg orally once per dayLocally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer161NA
no results
    no results